openPR Logo
Press release

Generic Injectable Market: Emerging Technological Enhancements & Global Future Forecasts

12-12-2018 03:47 PM CET | Health & Medicine

Press release from: Future Market Insights

Generic Injectable Market: Emerging Technological

Generic injectable drugs are those which have same active ingredient as innovator drug and is equivalent to its innovator drug in dosage form, safety, strength (dose), route of administration, performance, quality, and intended use. Some of the world’s largest manufacturers of sterile generic injectable have been making these drugs for over 80 years. Unlike branded sterile injectable drugs, generic injectable is cost-effective, especially cancer therapies, thus government in the majority of the countries are influencing to adopt generic injectable, in order to control healthcare spending. For instance, the global pharmaceutical industry is experiencing serious pricing issue and cost reduction pressure. e.g. North America pharmaceutical industry is growing at a sluggish rate of below 2% CAGR. A growth rate in Japan and Europe has seen never before decrease in drug prices. This, in turn, is impeding policy changes and encouraging use of generic injectable drugs in these key regions. Globally, a large number of generic drug makers are focusing on plant upgrades for an increase in captive manufacturing of sterile generic injectable drugs. Moreover, infamous regulatory delays in approval of sterile injectable drugs have contributed to the higher inclination towards investments in manufacturing of sterile generic injectable drugs in order to ensure higher quality. The average time period for regulatory approval for sterile drugs is over three to four years, however, that for bioequivalent sterile injectable is around 10-11 months. Faster regulatory approvals, low R&D investment, and the high margin are attracting manufacturers to invest in the generic injectable manufacturing.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6051

Generic Injectable Market: Drivers and Restraints

The global pharmaceutical industry is toning itself to fundamental changes in the marketplace and looking for new ways to achieve growth. Along with increasing efforts for manufacturing of sterile generic injectable, growing number of prescriptions for generic injectable is pushing the growth of the global generic injectable market. According to GPhA Conference report, 90% of injectable prescriptions in the U.S. in 2015 were for generic injectable, which is primarily driven by unprecedented series of patent expiration. Rapid expansion by key market players is another factor driving the growth of the global generic injectable market. Shortage of branded sterile injectable has further led to the adoption of generic injectable. Due to the complexity of manufacturing and stringency in the process, production of sterile injectable drugs is challenging and. This is causing frequent drug recalls due to safety issues. This can limit the growth of the global generic injectable market.

Generic Injectable Market: Segmentation

The global generic injectable market has been classified on the basis of product type, indication, distribution channel, and geography.

Based on product type, the global generic injectable market is divided into following:

Monoclonal Antibodies
Cytokines
Insulin
Vaccines
Others

Based on an indication, the global generic injectable market is divided into following:

Diabetes
Cancer
Cardiovascular Diseases
Infections
Others

Based on the disease type, the global generic injectable market is divided into following:

Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Prescription Stores

Generic Injectable Market: Overview

According to fact sheet published by Hospira Inc., approximately 1.5 Bn doses of generic injectable are sold every year across the globe. Monoclonal antibodies being the largest revenue generating segment, will continue to dominate the global generic injectable market over the forecast period. Other cluster consists of include opioid analgesics, general and local anesthetics, antidotes for opioid poisoning, skeletal muscle relaxants etc. Cancer and cardiovascular diseases indication segments are expected to represent highest growth opportunities over the forecast period due to the launch of several antibodies based generic injectable products.

Generic Injectable Market: Regional Overview

Geographically, the global generic injectable market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America holds the largest share in the global generic injectable market. Even though the generic injectable industry has operations across the globe, majority of largest manufacturers produce a large volume of generic injectable in the U.S. However, overseas manufacturing facilities of these manufacturers are subject to same stringent FDA regulations and facilities are inspected on regular basis. Moreover, in the U.S. over 70% of hospital patients receive generic injectable drugs, which is further pushing the demand for generic injectable in North America. Asia Pacific is expected to experience the highest increase in production volumes of generic injectable over the forecast period of 2017–2027. Countries such as China and India have growing pharmaceutical industry of their own. According to the latest report published by PwC, India is the global leader in the production of generics and vaccines. However, Europe is expected to experience sluggish growth due to an economic slowdown.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/toc/rep-gb-6051

Generic Injectable Market: Key Players

Some of the key players identified in the global generic injectable market are Pfizer Inc.(Hospira Inc. Pfizer Established Products), Baxter International, Sanofi SA, Novartis AG (Sandoz), GlaxoSmithKline plc., AstraZeneca plc., Fresenius SE & Co. KGaA, Johnson & Johnson, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company etc. among others. Majority of these companies have independent subsidiaries that operate in a sterile injectable manufacturing. Consolidation through acquisition and partnerships are emerging as prominent trends in the global generic injectable market. A rapid expansion of emerging players such as Amneal Pharmaceuticals, Endo International plc. Alvogen, ANI Pharmaceuticals Inc. etc. among others would significantly contribute to the growth of the global generic injectable market.

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic Injectable Market: Emerging Technological Enhancements & Global Future Forecasts here

News-ID: 1436203 • Views:

More Releases from Future Market Insights

Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Million by 2032
Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Milli …
The lithium-ion battery separator is a critical component in lithium-ion batteries, responsible for preventing short circuits and ensuring safe and efficient battery performance. It acts as a physical barrier between the positive and negative electrodes, allowing lithium ions to pass through while blocking the flow of electrons. With advancements in separator technology, these separators play a key role in enhancing battery capacity, cycle life, and overall safety in various applications,
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolstered by a Robust 7.1% CAGR from 2022
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolst …
The Industrial Drums Market is experiencing a steady and promising trajectory, with an estimated value of US$ 12.5 billion in 2022, projected to escalate to US$ 17.6 billion by 2027 at a commendable Compound Annual Growth Rate (CAGR) of 7.1%. This growth is substantiated by a 6.6% CAGR in volume during 2022-27, as per Future Market Insights. Anticipated to expand 1.5 times within this period, the market presents alluring prospects for industry
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of the Metal Cans Industry, Catering to Health-conscious and Environmentally-aware Consumers
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of …
The metal cans market is predicted to grow at a CAGR of 5% over the forecast period, according to research by Future Market Insights. The industry's estimated value is expected to increase from US$ 56 Bn in 2023 to US$ 91.1 Bn by 2033. The market for metal cans has been driven by the heightened demand for the product in food and beverages industry. Metal cans helps prolong shelf-life of perishable
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 with a 4.8% CAGR
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 …
The folding intermediate bulk containers (IBCs) market is on a growth trajectory, with an estimated value of US$ 418 million in 2022, projected to reach US$ 528 million by 2027, showcasing a Compound Annual Growth Rate (CAGR) of 4.8%. Remarkably, the China folding IBCs market defied initial pandemic-related skepticism and is anticipated to grow by 6.9% year on year in 2022. Despite global challenges, China's folding IBCs market is poised to contribute

All 5 Releases


More Releases for Generic

Generic Injectables Market growth is attributed to the increasing demand for Onc …
According to Precision Business Insights (PBI), the latest report, the generic injectables market will be worth USD 22.0 billion in 2022, growing at an 11.0% CAGR from 2022 to 2028. The global generic injectables market is segmented into the following types: Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital
A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise of
Generic Wellness Offers Special Discount on Generic Xenical for Fat Reduction !
This week a special offer is introduced by Generic Wellness for weight loss treatment with an oral drug called generic Xenical. The drug is an excellent weight loss treatment for all men and women above the age of 12. People who have taken this drug for weight loss have actually experienced the benefits like reduction of unwanted fat in the body. This is possible with generic Xenical because of the
Generic Drugs Market Trends 2025
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drugs Market - Global Competitive Analysis
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drug Market: Global Generic Drug Share to Reach USD 380.60 Billion by 20 …
Zion Market Research has published a new report titled “Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by